Nexalin Technology Inc
Exchange: NASDAQSector: HealthcareIndustry: Medical Devices
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.
Did you know?
Holds 654783.0x more cash than debt — a strong balance sheet.
Current Price
$0.38
+0.03%GoodMoat Value
$0.08
79.4% overvaluedProfile
Valuation (TTM)
Market Cap$7.10M
P/E-0.86
EV—
P/B1.89
Shares Out18.65M
P/Sales23.52
Revenue$301647.00
EV/EBITDA—
Nexalin Technology Inc (NXL) Stock News
NXL Stock News & Headlines
Latest stock news and headlines for Nexalin Technology Inc (NXL). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $0.38. Market cap: $7.10M. Sector: Healthcare. Industry: Medical Devices. This page aggregates the latest news articles relevant to NXL from financial news sources, helping investors stay current on events that may impact Nexalin Technology Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Nexalin Technology Inc (NXL).